Escure Guillaume, Manier Salomon
CHU Lille, hôpital Huriez, service d'hématologie, 59000 Lille, France; Université de Lille, Unité CANTHER, Inserm UMR-S1277 & CNRS UMR9020, 59000 Lille, France.
CHU Lille, hôpital Huriez, service d'hématologie, 59000 Lille, France; Université de Lille, Unité CANTHER, Inserm UMR-S1277 & CNRS UMR9020, 59000 Lille, France.
Bull Cancer. 2021 Oct;108(10S):S205-S212. doi: 10.1016/j.bulcan.2021.10.003.
Immunotherapies have recently emerged as potential game changers in the treatment of multiple myeloma (MM). Those include monoclonal antibodies (targeting CD38 or CS1), bispecific antibodies (BsAb, mainly targeting BCMA, GPRC5D or FcRH5), antibody-drug conjugate (mainly targeting BCMA) and CAR-T cells (mainly targeting BCMA). BsAb have the capacity to bind two different antigens, one at the tumor cell surface and one on T cells (CD3), recreating the immune synapse. In this article, we discuss the main clinical data on BsAb in MM, as well as their different constructs and the potential mechanism of resistance.
免疫疗法最近已成为多发性骨髓瘤（MM）治疗中潜在的游戏规则改变者。这些疗法包括单克隆抗体（靶向CD38或CS1）、双特异性抗体（BsAb，主要靶向BCMA、GPRC5D或FcRH5）、抗体药物偶联物（主要靶向BCMA）和嵌合抗原受体T细胞（CAR-T细胞，主要靶向BCMA）。BsAb能够结合两种不同的抗原，一种在肿瘤细胞表面，另一种在T细胞（CD3）上，从而重建免疫突触。在本文中，我们讨论了BsAb在MM中的主要临床数据，以及它们的不同构建体和潜在的耐药机制。
